InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report report published on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Performance

NYSE NSPR opened at $2.92 on Tuesday. The stock has a 50-day moving average of $2.59 and a 200 day moving average of $2.63. InspireMD has a one year low of $1.81 and a one year high of $3.42. The company has a market capitalization of $76.15 million, a price-to-earnings ratio of -3.89 and a beta of 0.93.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter in the prior year, the company earned ($0.15) earnings per share. On average, equities analysts predict that InspireMD will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

Several hedge funds have recently modified their holdings of the stock. Affiance Financial LLC purchased a new stake in shares of InspireMD during the 3rd quarter worth approximately $492,000. Parkman Healthcare Partners LLC bought a new stake in InspireMD in the third quarter worth about $279,000. Finally, Rosalind Advisors Inc. boosted its holdings in InspireMD by 266.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after acquiring an additional 1,827,579 shares during the period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.